Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
Combines BioSkyrb’s new ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit 384-well assay with Uno Single Cell Dispenser™ provided by Tecan in a single workflow Enables scalable, ...
Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...
This article and associated images are based on a poster originally authored by Marisa Amato and presented at ELRIG Drug Discovery 2025 in affiliation with Singleron Biotechnologies GmbH. This poster ...
Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
BioSkryb Genomics and Tecan Group, today introduced a high-throughput single-cell workflow, combining BioSkryb's 384-well format of the ResolveOME ™ Whole Genome and Transcriptome Single-Cell Core Kit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results